Recall Efforts Successfully Increase Follow-Up for Cervical Cancer Screening Among Women With Human Papillomavirus in Honduras.
Journal
Global health, science and practice
ISSN: 2169-575X
Titre abrégé: Glob Health Sci Pract
Pays: United States
ID NLM: 101624414
Informations de publication
Date de publication:
30 06 2020
30 06 2020
Historique:
received:
19
11
2019
accepted:
17
03
2020
entrez:
2
7
2020
pubmed:
2
7
2020
medline:
19
5
2021
Statut:
epublish
Résumé
Scaling up coverage of routine cervical screening in low-resource settings must be accompanied by efforts to retain women throughout the screening cascade and continuum of care, including adequate follow-up of abnormal results. The Scale-Up Project implemented human papillomavirus (HPV) testing for cervical cancer screening within public-sector health facilities in Honduras between 2015 and 2019. Women who were HPV-positive but did not have visually confirmed cervical lesions upon visual inspection with acetic acid (VIA-negative) were instructed to return to the health center after 1 year for repeat HPV testing. The current evaluation assessed the effectiveness of recall strategies to prompt women to return for retesting. Clinic staff placed reminder phone calls and followed up with short message service (SMS) or home visits, if needed. We summarized number of contacts, type of contacts, and time elapsed until return to the clinic, and used log-binomial regression to identify factors associated with return to the clinic. We identified 558 women who were initially HPV-positive VIA-negative from 8 clinics as needing repeat HPV testing 1 year later. Mean age was 43.2 years. Nearly all women (98.6%) were successfully contacted and 75.1% completed repeat HPV testing. The majority of contacts (65.4%) were phone calls, and nearly half of women who returned to the clinic (42.9%) did so after 1 contact. Mean days between contact and presentation at the clinic was 10.7 (standard deviation: 14.7). Women who required 3 or more contacts were 21% less likely to return for repeat HPV testing (prevalence ratio: 0.79; 95% confidence interval=0.69,0.90;
Identifiants
pubmed: 32606095
pii: GHSP-D-19-00404
doi: 10.9745/GHSP-D-19-00404
pmc: PMC7326516
doi:
Substances chimiques
Acetic Acid
Q40Q9N063P
Types de publication
Evaluation Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
290-299Informations de copyright
© Thomson et al.
Références
Psychooncology. 2017 Feb;26(2):161-172
pubmed: 27072589
J Infect Dis. 2011 Mar 15;203(6):814-22
pubmed: 21343148
Prev Med. 2020 Jun;135:106076
pubmed: 32247010
Salud Publica Mex. 2008 Jul-Aug;50(4):276-85
pubmed: 18670718
Br J Gen Pract. 2017 Aug;67(661):e580-e587
pubmed: 28716995
Pan Afr Med J. 2015 Jul 30;21:231
pubmed: 26523173
Eur J Cancer Care (Engl). 2017 Jan;26(1):
pubmed: 26853214
Br J Cancer. 2017 Nov 7;117(10):1557-1561
pubmed: 28881359
Papillomavirus Res. 2018 Dec;6:70-76
pubmed: 30391365
Cult Health Sex. 2013;15(6):637-51
pubmed: 23406345
Vaccine. 2008 Aug 19;26 Suppl 11:L37-48
pubmed: 18945401
Gynecol Oncol Rep. 2017 Mar 03;20:58-61
pubmed: 28337474
Cost Eff Resour Alloc. 2005 Nov 15;3:11
pubmed: 16288646
BMC Cancer. 2019 Apr 23;19(1):367
pubmed: 31014287
Int J Cancer. 2018 Aug 15;143(4):735-745
pubmed: 29341110
Int J Gynaecol Obstet. 2017 Jul;138 Suppl 1:63-68
pubmed: 28691331
BMC Cancer. 2017 Dec 13;17(1):847
pubmed: 29237420